Pang R, Jia Q, Ma C et al (2025) Alzheimers disease: the current and emerging treatment approaches
The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
Research protocols for BPC-157 typically use subcutaneous or oral administration
On the one hand, it positively regulates the mitochondrial fusion protein Mfn2, while on the other, it negatively regulates the expression of mitochondrial splitting-related proteins
Conclusion The study highlights the potential of targeting neurotrophic imbalances in autism therapy
Certain Medical Conditions Individuals with certain medical conditions, such as pernicious anemia, may experience B12 deficiency as their body cannot produce enough intrinsic factors, a protein necessary for B12 absorption
